A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
Clinical trial NCT05257083 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05257083
- Sponsor
- Stichting European Myeloma Network
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-10
- Primary completion
- 2033-06-01
- Enrollment
- 759
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.